Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Axitinib and renal cell cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Axitinib and renal cell cancer. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-003436-13 Sponsor Protocol Number: 105RC101 Start Date*: 2016-05-24
    Sponsor Name:TRACON Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Medical condition: ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Prematurely Ended) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-004098-23 Sponsor Protocol Number: Tide-A Start Date*: 2020-06-18
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001150-35 Sponsor Protocol Number: AxIn Start Date*: 2022-11-10
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study).
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004562-16 Sponsor Protocol Number: ICR-CTSU/2011/10033 Start Date*: 2012-05-15
    Sponsor Name:Institute of Cancer Research [...]
    1. Institute of Cancer Research
    2. The Royal Marsden Hospital NHS Foundation Trust
    Full Title: A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-000588-17 Sponsor Protocol Number: MK-3475-426 Start Date*: 2016-12-01
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally A...
    Medical condition: Advanced Kidney Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2015-002429-20 Sponsor Protocol Number: B9991003 Start Date*: 2016-08-05
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA®) VERSUS SUNITINIB (SUTENT®) ) MONOTHERAPY IN THE FIRST-LINE TRE...
    Medical condition: Advanced renal cell carcinoma (aRCC).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10023405 Kidney cancer stage IV LLT
    21.0 100000004864 10023404 Kidney cancer stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Ongoing) SE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) AT (Completed) DK (Completed) ES (Temporarily Halted) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000619-17 Sponsor Protocol Number: NAXIVA1.0 Start Date*: 2017-08-02
    Sponsor Name:Common Services Agency (CSA)
    Full Title: Phase II neoadjuvant study of Axitinib for reducing extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion.
    Medical condition: Venous tumour thrombus in clear cell renal cell cancer with venous invasion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-001451-21 Sponsor Protocol Number: A4061032 Start Date*: 2008-06-18
    Sponsor Name:Pfizer Inc.,235 East 42nd Street,New York,NY 10017
    Full Title: AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
    Medical condition: Renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) AT (Completed) FR (Completed) GB (Completed) IE (Completed) DE (Completed) IT (Completed) PL (Completed) GR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-000399-28 Sponsor Protocol Number: AIO-NZK-0115/ass. Start Date*: 2016-12-06
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of pembrolizumab + axitin...
    Medical condition: advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006430-39 Sponsor Protocol Number: BO43936 Start Date*: 2023-03-07
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED OPEN LABEL PHASE II STUDY OF IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC RENAL CELL CARCINOMA
    Medical condition: Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    25.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10086821 Advanced renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001065-21 Sponsor Protocol Number: ET21-023 Start Date*: 2021-10-12
    Sponsor Name:CENTRE LEON BERARD
    Full Title: PAXIPEM - Multicenter phase II study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC)
    Medical condition: Locally advanced or metastatic papillary cell carcinoma (PRCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002190-33 Sponsor Protocol Number: B1131004 Start Date*: 2012-02-02
    Sponsor Name:PFIZER, S.L.U.
    Full Title: A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN 2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA
    Medical condition: METASTATIC RENAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) CZ (Completed) DE (Prematurely Ended) GB (Completed) AT (Completed) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003905-24 Sponsor Protocol Number: AP311736 Start Date*: 2014-02-12
    Sponsor Name:SFJ Pharma Ltd. II
    Full Title: ADJUVANT AXITINIB TREATMENT OF RENAL CANCER: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT AXITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RCC
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018585-23 Sponsor Protocol Number: A4061051 Start Date*: 2010-12-21
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017
    Full Title: AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC)
    Medical condition: metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-004345-24 Sponsor Protocol Number: B9991027 Start Date*: 2018-09-26
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York,NY 10017
    Full Title: A PHASE 2, OPEN LABEL STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB (BAVENCIO) IN COMBINATION WITH AXITINIB (INLYTA) IN PATIENTS WITH ADVANCED OR METASTATIC PREVIOUSLY TREATED NON-SMAL...
    Medical condition: Advanced or Metastatic previously treated non-small cell lung cancer or treatment naïve cisplatin-ineligible urothelial cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-006009-85 Sponsor Protocol Number: 1 Start Date*: 2012-06-04
    Sponsor Name:VU University medical center
    Full Title: Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients
    Medical condition: Advanced solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007786-23 Sponsor Protocol Number: A4061046 Start Date*: 2009-04-23
    Sponsor Name:Pfizer, S.A.
    Full Title: ESTUDIO EN FASE 2 ALEATORIZADO Y DOBLE CIEGO DE AXITINIB (AG-013736) CON O SIN AJUSTE DE LA DOSIS EN PACIENTES CON CANCER DE CELULAS RENALES METASTASICO RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF A...
    Medical condition: CCR metastásico Metastatic RCC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020447-13 Sponsor Protocol Number: CRAD001L2404 Start Date*: 2012-08-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multicenter phase II study to examine the efficacy and safety of everolimus as second-line therapy in the treatment of patients with metastatic renal cell carcinoma
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-001455-32 Sponsor Protocol Number: WIN001 Start Date*: 2017-12-15
    Sponsor Name:Worldwide Innovative Network Association
    Full Title: A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to mat...
    Medical condition: Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (EGFR mutation, ALK translocation, ROS1 mutation if available or MET exon 14 skipping ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005939-78 Sponsor Protocol Number: C-II-008 Start Date*: 2012-06-25
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research-EWIV
    Full Title: A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study)
    Medical condition: metastatic renal cell carcinoma (mRCC)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:38:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA